ESC Premium Access

Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension

Congress Presentation

About the speaker

Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)
15 presentations
2 followers

7 more presentations in this session

Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis

Speaker: Doctor V. Algalarrondo (Paris, FR)

Thumbnail

Increased index of microcirculatory resistance, capillary rarefaction, elevated troponin levels, and their association with transthyretin amyloidosis cardiomyopathy

Speaker: Mr Y. Suiko (Miyazaki, JP)

Thumbnail

Association of cardiac amyloidosis with cardiovascular outcomes after aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Speaker: Doctor T. Figueira (Stony Brook, US)

Thumbnail

Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.

Speaker: Doctor P. Debonnaire (Brugge, BE)

Thumbnail

RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.

Speaker: Doctor S. Schwarting (Munich, DE)

Thumbnail

Access the full session

Cardiac amyloidosis: diagnosis and outcomes

Speakers: Doctor M. Maurer, Doctor V. Algalarrondo, Mr Y. Suiko, Doctor T. Figueira, Doctor P. Debonnaire...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations